Tag: Drug Approvals
FDA Approves Eohilia for Eosinophilic Esophagitis
Approval allows for twice daily oral treatment for 12 weeks in people aged 11 years and older
FDA Approves Aurlumyn for Severe Frostbite
Newly approved medication lowers the need for amputation of fingers or toes
FDA Approves Onivyde Combination for Metastatic Pancreatic Cancer
Approval allows Onivyde (plus oxaliplatin, fluorouracil, and leucovorin) as first-line therapy
FDA Approves Ogsiveo for Desmoid Tumors
Approval marks first approved systemic treatment for the rare cancer
FDA Approves First Treatment for Congenital Thrombotic Thrombocytopenic Purpura
The genetically engineered protein product is safe, effective for the rare inherited blood clotting disorder
FDA Approves New Diet Drug Zepbound, a Version of the Diabetes Med Mounjaro
Zepbound works by activating hormone receptors in the body to reduce appetite and food intake
FDA Approves Voquezna for Erosive Esophagitis, GERD
Phase 3 trial showed noninferiority versus lansoprazole in healing and maintenance phases
FDA Approves Zilbrysq for Generalized Myasthenia Gravis
Approval granted for once-daily, self-administered treatment in patients with anti-acetylcholine receptor-antibody-positive disease
FDA Approves Nivolumab as Adjuvant Treatment for Melanoma
Approval granted for patients aged 12 years and older with stage IIB/C disease
FDA Approves Velsipity for Moderate-to-Severe Ulcerative Colitis in Adults
Significant benefits at 12 weeks include clinical remission, endoscopic improvement, mucosal healing
